News | September 29, 2008

GE Acquires Biomedical, Pharmaceutical Research Group

September 30, 2008 - GE Healthcare (GE) has acquired MicroCal LLC, a provider of instruments for the study of molecular interactions in pharmaceutical, biomedical and life science research, as GE moves to expand its offering for protein science and drug discovery research.

MicroCal develops and manufactures microcalorimeters that provide detailed information on the structure, function and binding properties of a wide range of biomolecules such as proteins, lipids, nucleic acids and antibodies. The growing trend towards structure-based drug design together with the expansion in biopharmaceutical development is driving an increase in the use of microcalorimetry as a standard technique in pharmaceutical research.

MicroCal’s proprietary technology, which is complementary to GE Healthcare’s Biacore platform, provides scientists with detailed information across several stages of the drug discovery process, reducing the potential for late-stage drug candidate failures. MicroCal’s technology is already used in over one thousand laboratories worldwide.

Peter Ehrenheim, president and CEO of GE Healthcare’s Life Sciences business, said, “MicroCal is a company with a strong reputation for innovation in microcalorimetry and is a great strategic fit with our Life Sciences business. The combination of GE Healthcare’s expertise in protein science together with the talent of the team at MicroCal will help us drive development of new technologies and create an extensive offering across the full spectrum of the drug discovery and development process.”

GE Healthcare plans to develop the MicroCal facility in Northampton, MA into a center of excellence for microcalorimetry. This acquisition is consistent with GE's strategy to invest in high-technology, innovative businesses that deliver strong top-line growth and expanded margins.

"We are very excited to be part of GE Healthcare,” said Richard Brown, CEO, MicroCal. "We see great potential for this business. The resources of GE Healthcare and the wider GE group will allow us to significantly widen our reach and to jointly develop new technologies, products and applications which will help scientists increase their understanding of molecular interactions. The MicroCal team very much looks forward to working with GE Healthcare’s leadership to realize the potential of this great technology.”

For more information: www.gehealthcare.com

Related Content

CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
The Siemens Biograph Vision PET-CT system was released in mid-2018.

The Siemens Biograph Vision PET-CT system was released in mid-2018.

Feature | Nuclear Imaging | September 07, 2018 | By Dave Fornell
Nuclear imaging technology for both single photon emission computed tomography (SPECT) and positron emission tomography...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Abnormal Protein Concentrations Found in Brains of Military Personnel With Suspected CTE

Researchers are using the tracer, which is injected into a patient, then seen with a PET scan, to see if it is possible to diagnose chronic traumatic encephalopathy in living patients. In this image, warmer colors indicate a higher concentration of the tracer, which binds to abnormal proteins in the brain. Credit UCLA Health.

News | PET Imaging | August 24, 2018
August 24, 2018 — In a small study of
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...